Overview

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well chemotherapy and peripheral stem cell transplant work in treating patients with multiple myeloma or primary systemic amyloidosis.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Herbert Irving Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Busulfan
Cyclophosphamide
Interferon-alpha
Interferons
Melphalan
Sargramostim
Criteria
DISEASE CHARACTERISTICS:

- Histologically confirmed multiple myeloma OR

- Primary systemic amyloidosis resulting in significant organ dysfunction and decreased
quality of life

- Complete or partial response after standard chemotherapy

- Primary refractory or relapsed multiple myeloma after first-line treatment with
standard chemotherapy

- Ineligible for higher priority national or institutional clinical studies

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-2

Life expectancy:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- Bilirubin less than 2 times normal

Renal:

- Creatinine less than 2.5 mg/dL or on stable hemodialysis

Cardiovascular:

- LVEF at least 45%

Pulmonary:

- DLCO at least 60% of predicted OR

- Approval by pulmonologist

Other:

- HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Concurrent participation in gene therapy trials allowed

Chemotherapy:

- See Disease Characteristics

- No other concurrent chemotherapy

Endocrine therapy:

- No concurrent steroids as antiemetics during chemotherapy

- No concurrent anticancer hormonal therapy

Radiotherapy:

- Not specified

Surgery:

- Not specified

Other:

- No concurrent barbiturates or acetaminophen during chemotherapy

- Concurrent participation in supportive care trials allowed